Ikena Oncology
As of the edition of 20 October 2026, Ikena Oncology runs 8 drugs; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 5 |
| Status not established | 2 |
| Total | 8 |
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Ikena Oncology needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 6 trials led
- Cancer: 4 trials led
- Immune system: 4 trials led